[HTML][HTML] Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
SR McCurdy, YL Kasamon, CG Kanakry… - …, 2017 - ncbi.nlm.nih.gov
Composite endpoints that not only encompass mortality and relapse, but other critical post-transplant
events such as graft-versus-host disease, are being increasingly utilized to quantify …
events such as graft-versus-host disease, are being increasingly utilized to quantify …
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
SR McCurdy, JA Kanakry, MM Showel… - Blood, The Journal …, 2015 - ashpublications.org
Related HLA-haploidentical blood or marrow transplantation (BMT) with high-dose
posttransplantation cyclophosphamide (PTCy) is being increasingly used because of its acceptable …
posttransplantation cyclophosphamide (PTCy) is being increasingly used because of its acceptable …
NCCN Guidelines® insights: myelodysplastic syndromes, version 3.2022: featured updates to the NCCN guidelines
…, Y Madanat, LJ Maness, J Mangan, S McCurdy… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for
the evaluation, diagnosis, and management of patients with MDS based on a review of …
the evaluation, diagnosis, and management of patients with MDS based on a review of …
Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide
SR McCurdy, MJ Zhang, A St. Martin… - Blood …, 2018 - ashpublications.org
We studied the association between non-HLA donor characteristics (age, sex, donor-recipient
relationship, blood group [ABO] match, and cytomegalovirus [CMV] serostatus) and …
relationship, blood group [ABO] match, and cytomegalovirus [CMV] serostatus) and …
[HTML][HTML] Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease
…, AR Girshick, C O'Dushlaine, SR McCurdy… - Nature …, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters human host cells
via angiotensin-converting enzyme 2 (ACE2) and causes coronavirus disease 2019 (COVID-…
via angiotensin-converting enzyme 2 (ACE2) and causes coronavirus disease 2019 (COVID-…
Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell–replete haploidentical donor transplantation using post-transplant …
A Bashey, MJ Zhang, SR McCurdy… - Journal of Clinical …, 2017 - ascopubs.org
Purpose T-cell–replete HLA-haploidentical donor hematopoietic transplantation using post-transplant
cyclophosphamide was originally described using bone marrow (BM). With …
cyclophosphamide was originally described using bone marrow (BM). With …
[HTML][HTML] Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults
…, GT Prince, HL Tsai, SR McCurdy… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or
marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated …
marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated …
[HTML][HTML] Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects
…, N Berkowitz, DA Turrisini, M Gaddis, SR McCurdy… - Nature …, 2022 - nature.com
Multiple COVID-19 genome-wide association studies (GWASs) have identified reproducible
genetic associations indicating that there is a genetic component to susceptibility and …
genetic associations indicating that there is a genetic component to susceptibility and …
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
EJ Fuchs, SR McCurdy, SR Solomon… - Blood, The Journal …, 2022 - ashpublications.org
Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly
used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor …
used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor …
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
…, S Gier, C Cho, HK Tsai, S McCurdy… - Blood, The Journal …, 2022 - ashpublications.org
Older patients with acute myeloid leukemia (AML) have high relapse risk and poor survival
after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive …
after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive …
